The Aurora A and B kinases are up-regulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets


Autoria(s): Careta, Francisco de Paula; Gobessi, Stefania; Panepucci, Rodrigo Alexandre; Bojnik, Engin; de Oliveira, Fabio Morato; Matos, Daniel Mazza; Falcao, Roberto P.; Laurenti, Luca; Zago, Marco A.; Efremov, Dimitar G.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

29/10/2013

29/10/2013

2012

Resumo

Background The malignant B cells in chronic lymphocytic leukemia receive signals from the bone marrow and lymph node microenvironments which regulate their survival and proliferation. Characterization of these signals and the pathways that propagate them to the interior of the cell is important for the identification of novel potential targets for therapeutic intervention. Design and Methods We compared the gene expression profiles of chronic lymphocytic leukemia B cells purified from bone marrow and peripheral blood to identify genes that are induced by the bone marrow microenvironment. Two of the differentially expressed genes were further studied in cell culture experiments and in an animal model to determine whether they could represent appropriate therapeutic targets in chronic lymphocytic leukemia. Results Functional classification analysis revealed that the majority of differentially expressed genes belong to gene ontology categories related to cell cycle and mitosis. Significantly up-regulated genes in bone marrow-derived tumor cells included important cell cycle regulators, such as Aurora A and B, survivin and CDK6. Down-regulation of Aurora A and B by RNA interference inhibited proliferation of chronic lymphocytic leukemia-derived cell lines and induced low levels of apoptosis. A similar effect was observed with the Aurora kinase inhibitor VX-680 in primary chronic lymphocytic leukemia cells that were induced to proliferate by CpG-oligonucleotides and interleukin-2. Moreover, VX-680 significantly blocked leukemia growth in a mouse model of chronic lymphocytic leukemia. Conclusions Aurora A and B are up-regulated in proliferating chronic lymphocytic leukemia cells and represent potential therapeutic targets in this disease.

Italian Association for Cancer Research (AIRC, Milan, Italy)

Italian Association for Cancer Research (AIRC, Milan, Italy) [5917]

Leukemia & Lymphoma Society (LLS, White Plains, NY) [R6170-10]

Leukemia & Lymphoma Society (LLS, White Plains, NY)

State of Sao Paulo Research Foundation (FAPESP), Brazil

State of Sao Paulo Research Foundation (FAPESP, Brazil)

National Council for Scientific and Technological Development (CNPq, Brazil)

National Council for Scientific and Technological Development (CNPq), Brazil

FAPESP

FAPESP

ICMJE

ICMJE

Identificador

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, PAVIA, v. 97, n. 8, supl. 1, Part 4, pp. 1246-1254, AUG, 2012

0390-6078

http://www.producao.usp.br/handle/BDPI/36331

10.3324/haematol.2011.054668

http://dx.doi.org/10.3324/haematol.2011.054668

Idioma(s)

eng

Publicador

FERRATA STORTI FOUNDATION

PAVIA

Relação

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL

Direitos

closedAccess

Copyright FERRATA STORTI FOUNDATION

Palavras-Chave #CHRONIC LYMPHOCYTIC LEUKEMIA #MICROENVIRONMENT #AURORA KINASE #NOVEL THERAPEUTIC TARGETS #SMALL-MOLECULE INHIBITOR #NF-KAPPA-B #FOSTAMATINIB DISODIUM #MULTIPLE-MYELOMA #TRANSGENIC MOUSE #ANTIGEN-RECEPTOR #TUMOR-GROWTH #IN-VIVO #SURVIVAL #CLL #HEMATOLOGY
Tipo

article

original article

publishedVersion